Larvol Delta - Innovent-Announces-First-Patient-Dosed-in-the-Phase-3-Clinical-Study-STAR-of-Efdamrofusp-Alfa-IBI302-a-Firstinclass-Ophthalmic-AntiVEGF-and-AntiComplement-Bispecic-Fusion-Protein-for-the-Treatment-of-Neovascular-Agerelated-Macular-Degeneration

efdamrofusp alfa (IBI302) - Innovent Biologics

https://www.prnewswire.com/news-releases/innovent-announces-first-patient-dosed-in-the-phase-3-clinical-study-star-of-efdamrofusp-alfa-ibi302-a-first-in-class-ophthalmic-anti-vegf-and-anti-complement-bispecific-fusion-protein-for-the-treatment-of-neovascular-age-rel-301950190.html

Oct 8, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next